CCR4 and adult T-cell leukemia/lymphoma: Mogamulizumab, a defucosylated anti-CCR4 antibody developed in Japan, is crucial in adult T-cell leukaemia/lymphoma (ATLL) [25], cutaneous T-cell lymphomas, and peripheral T cell lymphomas [26].